| Identification | Back Directory | [Name]
PCI 29732 | [CAS]
330786-25-9 | [Synonyms]
CS-2698
PCI 29732
PCI 29732;PCI29732;PCI-29732
PCI 29732 (This product is only available in Japan.)
1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-cyclopentyl-3-(4-phenoxyphenyl)- | [Molecular Formula]
C22H21N5O | [MDL Number]
MFCD25976874 | [MOL File]
330786-25-9.mol | [Molecular Weight]
371.43 |
| Chemical Properties | Back Directory | [Boiling point ]
599.6±50.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 20 mg/ml; DMF:PBS (pH 7.2) (1:2): 0.3 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml | [form ]
Powder | [pka]
4.24±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PCI 29732 (cas# 330786-25-9) is a useful research chemical. It is a COVID19-related research product. | [Definition]
ChEBI: 1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine is an aromatic ether. | [in vivo]
PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents[2].
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model[2]. | Animal Model: | 5-6 weeks old athymic nude mice (bearing H460/MX20 cells)[2] | | Dosage: | 20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration) | | Administration: | P.o.; every 3 d × 5 times | | Result: | Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.
|
| [storage]
Store at -20°C |
|
|